Videos

Key opinion leaders examine the comparative safety profiles and response durations of combination therapy versus monotherapy in the treatment of BCG-unresponsive carcinoma in situ with or without papillary disease.

"A lot of studies were done in a way that weren't randomized," says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.

"We hypothesize that when we treat female sexual dysfunction, we can ultimately improve the dynamics between the couple, and therefore improve the male partner satisfaction with his IPP," says Thairo Pereira, MD.

"We're actually standardizing how to clean the catheter, because the system tells you exactly [how]," says Ana Lidia Flores-Mireles, PhD.

“Sometimes there's some difficulties with continuity of care, because I'm not the sole provider for that patient,” says Robert D. Hoy, MPAS, PA-C.

"The number of treatment centers that are offering stereotactic body radiation [grew] over the course of the study," says Michael Stencel, DO.

Dean Elterman, MD, covers minimally invasive surgical therapies (MIST) for BPH, including laser therapy, prostatic urethral lift, and others, their impact on BPH management, AUA guidelines, patient selection, and the role of patient preference in choosing between MIST, medication, and surgery.

"I actually worked with several different urologists while we were developing this," says Jennifer Ann Meddings, MD.

Dean Elterman, MD, discusses historical treatment options for BPH, including both pharmacotherapy and surgical methods, their effectiveness, and how to identify patients who would benefit from treatment based on quality of life, risk of lower urinary tract symptoms, and other factors. It also addresses challenges such as long-term complications and patient adherence.

"We ended up with 3091 participants overall, and 3 trends came out that were significant," says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.

Key opinion leaders discuss considerations for sequencing androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer, evaluating their benefits in first-line versus second-line treatment settings.

Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.

“The great news is that we have now completed recruitment. We actually recruited more than 1700 patients,” says Kari A.O. Tikkinen, MD, PhD.

"I think having both the clinical and the research piece is very complementary and really helps to keep me feeling happy and motivated," says Stacy Loeb, MD, MSc, PhD (Hon).

Medical oncologists explore risk stratification strategies for newly diagnosed patients with prostate cancer, emphasizing the significant role of the Gleason score in diagnosis and prognosis.

The key opinion leaders explore risk factors for prostate cancer, detailing both general risk groups and high-risk populations more susceptible to developing the disease.

"There are actually no clear guidelines on when to refer patients with nephrolithiasis to genetic testing," says Nicolette G. Payne, MD.

“One of our goals here with our program is to hopefully expand the APPs in the sexual medicine field,” says Kristy L. Mardis, NP.

"One of the things that's been identified is over 90% of the UTI presentations have found bugs that are antibiotic resistant," says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.

Experts on prostate cancer discuss the relationship between prostate cancer and cardiovascular disease, highlighting ongoing research for safer treatment.

Focusing on castration-resistant prostate cancer, the panel reviews treatment options for patients with metastatic and nonmetastatic disease.

“In addition, the average levels of the medication in the bloodstream, at least during the first 30 minutes, was higher,” says Steven A. Kaplan, MD.

"Our goal is that people would not be getting catheterized when they actually do not have sufficient urinary retention," says Jennifer Ann Meddings, MD.

Experts discuss the results of the CORE-001 Trial.

Experts compare Cretostimogene and BCG Administration Methods

"Pathogens can stay there for a long time, even if the contamination was really quick...It happens really fast," says Ana Lidia Flores-Mireles, PhD.

"We have incredible data based on long-term follow up that help us understand what the right therapy is for kids, primarily kids with neurologic diseases like spina bifida," says Rosalia Misseri, MD, FAAP.

"I think what's really important for this is that you counsel patients before they undergo testing," says Nicolette G. Payne, MD.

Key opinion leaders explore the role of androgen receptor-targeted therapy in mCRPC.